MorphoSys (Germany)

Recent papers from MorphoSys (Germany)

1. Gelatin-Based Coating for the Controlled and Localized Delivery of Tetrabranched Antimicrobial Peptide in Cardiac Implantable DevicesACS Applied Bio Materials · 2026
2. Legendre Polynomials and an Inequality for a Combinatorial SumAxioms · 2026
3. Impact of colostrum processing on metabolic and endocrine parameters during early postnatal life in calvesJournal of Dairy Science · 2026
4. Feeding 2-fold upconcentrated versus native colostrum modulates systemic immunity, metabolism, and fecal profile in neonatal calvesJournal of Dairy Science · 2026
5. Gaps, Needs, and Potential Solutions for Cloud-Native Data in Natural and Engineering Sciences2026
6. The Challenges of Standardization2026
7. Inequalities for the Lambert seriesThe Ramanujan Journal · 2026
8. Colostral fat content modulates glucose homeostasis and lipid metabolism in neonatal calves exposed to cold temperatureJournal of Dairy Science · 2026
9. WCN26-1872 PRESERVATION OF HUMORAL IMMUNITY AND RESPONSE TO VACCINATION AND INFECTION IN FELZARTAMAB-TREATED PATIENTS WITH IgA NEPHROPATHY: DATA FROM THE PHASE 2 IGNAZ STUDYKidney International Reports · 2026
10. 20: Clinical Investigation on the “Synchronized Cardiac Support” Treatment in Patients with Cardiogenic Shock – Rational and DesignASAIO Journal · 2026
11. Expanding the payload scope in antibody-drug conjugates by delivery of hydroxy-containing drugs through self-immolative phosphoramidatesNature Communications · 2026
12. Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 studyThe Oncologist · 2025
13. Transfer of Intravenous Remimazolam into Milk of Lactating Sheep and Uptake by Breast-fed LambsCurrent Drug Metabolism · 2025
14. Remission Assessment by Circulating Tumor DNA in Large B-cell LymphomaJournal of Clinical Oncology · 2025
15. Analytical Data and Single-Dose PK are Sufficient to Conclude Comparable Immunogenicity for Biosimilars: An Ustekinumab Case StudyBioDrugs · 2025
16. Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathyKidney International · 2025
17. Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trialNature Medicine · 2025
18. Enhanced Prenatal and Postnatal Development Study in Marmoset Monkeys Following Administration of FelzartamabInternational Journal of Toxicology · 2024
19. Updated Results from the Phase 3 Manifest-2 Study of Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor-Naïve Patients with MyelofibrosisBlood · 2024
20. New Ustekinumab Biosimilar Candidate FYB202: Pharmacokinetic Equivalence Demonstrated in a Randomized, Double‐Blind, Parallel‐Group, Single‐Dose Trial in Healthy SubjectsClinical Pharmacology in Drug Development · 2024